A5017736098- Protein purification and stability
- Advanced Drug Delivery Systems
- Microencapsulation and Drying Processes
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Blood properties and coagulation
- Occupational and environmental lung diseases
- Coagulation and Flocculation Studies
- Drug Solubulity and Delivery Systems
- Lung Cancer Treatments and Mutations
- RNA Interference and Gene Delivery
- Extracellular vesicles in disease
- Transgenic Plants and Applications
- Microbial Inactivation Methods
- Nanoparticle-Based Drug Delivery
- Occupational exposure and asthma
Boehringer Ingelheim (Germany)
2024
Ludwig-Maximilians-Universität München
2021-2022
Abstract Extracellular vesicles (EV) are an emerging technology as immune therapeutics and drug delivery vehicles. However, EVs usually stored at −80 °C which limits potential clinical applicability. Freeze‐drying of striving for long‐term stable formulations is therefore studied. The most appropriate formulation parameters identified in freeze‐thawing studies with two different EV types. After a freeze‐drying feasibility study, four lyophilized tested storage stability up to 6 months....
Producing amorphous solid dispersions (ASDs) by hot-melt extrusion (HME) is favorable from an economic and ecological perspective but also limited to thermostable active pharmaceutical ingredients (APIs). A potential technology shift spray-drying at later stages of drug product development a desirable goal, however bearing the risk insufficient comparability in vitro vivo performance final dosage form. Hot-melt was performed using API/polymer/surfactant mixtures with hydroxypropyl...
Fibrogenic processes instigate fatal chronic diseases leading to organ failure and death. Underlying biological involve induced massive deposition of extracellular matrix (ECM) by aberrant fibroblasts. We subjected diseased primary human lung fibroblasts an advanced three-dimensional phenotypic high-content assay screened a repurposing drug library small molecules for inhibiting ECM deposition. Fibrotic Pattern Detection Artificial Intelligence identified tranilast as effective inhibitor....
Idiopathic pulmonary fibrosis (IPF) represents a progressive interstitial lung disease with mean survival time of 3-5 years. Approved pharmacological therapies may slow down, but not stop progression. IPF pathogenesis is characterized by the deposition excessive amounts fibrotic extracellular matrix activated myofibroblasts resulting in loss function. We developed phenotypic drug discovery assay measuring ECM primary human fibroblasts (pHLFs) derived from patients treated transforming growth...